Sequenom, which will be acquired by LabCorp this year, saw an increase in testing for average-risk pregnancies in the quarter, despite lower overall revenues.
The firm also reported that it has corrected immaterial errors in previous financial statements.
Test volume growth for its Panorama NIPT and Horizon carrier screening tests drove its revenues gains year over year.
Diagnostic systems strength was driven by strong growth in molecular and installations in Western Europe .
The firm's life science sales were driven by increased sales for its Droplet Digital PCR and process chromatography products.
The revenue growth was driven by increased demand for the company's Afirma gene expression classifier test, which differentiates benign thyroid nodules from cancerous ones.
The company credited the increased revenues to a 12 percent rise in the number of Oncotype Dx tests delivered.
The company also said that its FoundationOne test has been accepted for parallel review as part of the Expedited Access Pathway program with the FDA and CMS.
The company will soon submit its ePlex instrument and respiratory pathogen panel for US Food and Drug Administration clearance.
For the three months ended June 30, Qiagen reported net sales of $334.4 million, exceeding the Wall Street estimate of $326.8 million.